Awarded contract
Published
Markedshøring Oncotype DX
52 Suppliers have already viewed this notice
Track & Win Public Sector Contracts and Tenders. Sign up for Free
Buyer
Close date
2025-01-17
Description
Region Zealand is assisting the Danish Health Technology Council in conducting a market consultation about the existence of any CE marked non-invasive prognostic test to guide adjuvant chemotherapy treatment decisions for individuals with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage (I-IIIa) invasive breast cancer. The test provides two pieces of information: 1. the recurrence risk and 2. the benefit of adding chemotherapy in order to reduce the risk. The test analyses the expression of 21 genes in breast tumour tissue based on RT-PCR. It does not require additional tumour material beyond the surgically excised tissue. This is the case because a company has requested the Danish Health Technology Council to assess their non-invasive prognostic test to guide adjuvant chemotherapy treatment decisions for individuals with HR+, HER2-, I-IIIa invasive breast cancer.
Personalised AI Summary
Unlock decision maker contacts.
Create a Free Account on Stotles
Stotles is your single source for government tenders, contracts, frameworks and much more. Sign up for free.
Explore similar pre-tenders, open or awarded contracts
Browse open tenders, recent contract awards and upcoming contract expiries that match similar CPV codes.
Region Sjælland
–
Published 5 months ago
Danmarks Tekniske Universitet - DTU
–
Published 9 months ago
Region Nordjylland
–
Published a year ago
Explore top buyers for public sector contracts
Discover open tenders, contract awards and upcoming contract expiries of thousands of public sector buyers below. Gain insights into their procurement activity, historical purchasing trends and more.
CPV Codes
Sign up to the Stotles Tender Tracker for free
Find even more contracts with advanced search capability and AI powered relevance scoring.